Services

Capital Markets

We are well-versed in the legal and regulatory requirements for listing on the Mainboard and Catalist Board of the Singapore Exchange Securities Trading Limited (SGX-ST). Staying current and relevant on SGX-related issues is of top priority to us, and our Directors also have experience with capital markets overseas, including NASDAQ, Hong Kong, Shenzhen PRC and Malaysia.

We help our clients meet the challenges of raising funds through all types of equity and debt capital market transactions. We have experience with initial public offerings (IPOs) and secondary fund-raising, including rights issues and share placements, and debt securities such as convertible notes and warrants.

Recent notable transactions we have undertaken in this area:

  • Advising SGX Catalist-listed Bromat Holdings Ltd (formerly known as No Signboard Holdings Ltd) on the proposed renounceable non-underwritten rights issue of up to 154,129,586 new ordinary shares at an issue price of S$0.042 per share, on the basis of one (1) rights share for every two (2) existing ordinary shares, as announced on 14 January 2025 via SGXNet
  • Advised SGX Catalist-listed GS Holdings Limited on the renounceable non-underwritten rights issue of up to 570,888,708 new ordinary shares at an issue price of S$0.015 per share, on the basis of two (2) rights shares for every one (1) existing ordinary share, completed on 8 October 2024
  • Advised SGX Catalist-listed Quantum Healthcare Limited on its (i) S$800,000 private placement involving an allotment and issuance of 400,000,000 new ordinary shares at the placement price of $0.002 per placement share to two placees procured by the company, (ii) S300,000 settlement shares issuance involving an allotment and issuance of 150,000,000 new ordinary shares at the settlement price of $0.002 per settlement share to a creditor of the company, both completed on 15 February 2024
  • Advised SGX Catalist-listed Quantum Healthcare Limited on its approximately S$2,000,000 private placement involving an allotment and issuance of 571,428,600 new ordinary shares at the placement price of $0.003 per placement share to subscribers procured by a placement agent, completed on 30 March 2023.